MNZ welcomes PHARMAC decision to fund melanoma treatment

Melanoma New Zealand welcomes PHAMAC decision to fund New Zealand’s first effective treatment for advanced melanoma

Melanoma New Zealand is relieved that PHARMAC has agreed to fund an immunotherapy treatment for advanced melanoma, preventing avoidable deaths for Kiwis with melanoma.

New Zealand has the highest incidence of melanoma in the world with 4,500 new cases of the disease diagnosed each year, and more than 300 New Zealanders losing their lives every year from melanoma.

“The funding of a break-through treatment has the power to change these statistics for the better and give patients hope. Access to a funded treatment option that’s proven to be effective in treating malignant melanoma will, quite simply, save lives,” said Linda Flay, CEO of Melanoma Foundation.

From 1 July 2016, nivolumab (brand name Opdivo) will be funded for people with advanced melanoma. This will be available through their specialist and will be administered via an infusion in a DHB hospital clinic.

“We want to acknowledge and honour the many patients and their loved ones who have campaigned tirelessly to achieve this change. We believe that their commitment and determination has achieved a positive result and leaves a legacy that will benefit many New Zealanders and their families in the years to come.”

“We need to ensure equitable access to this break-through treatment to ensure all patients who are eligible receive the best treatment regardless of where they live,” she added.

OPVIDO shrinks or stabilises melanoma tumours in the majority of patients with advanced melanoma and lengthens the survival of these people. More than one-third of people treated with OPVIDO are still alive five years after starting treatment.

ENDS

© Scoop Media